Ipsen SA
IPN: XPAR (FRA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|md | LOCK|Q&m? | LOCK|S$P@!<! |
Ipsen Earnings: Broad-Based Growth Supports Confidence Beyond Somatuline
Ipsen reported third-quarter sales of EUR 1.17 billion, up 28% from the prior-year period. Management raised its 2026 guidance for total sales growth to around 23% at constant exchange rates (previously 20%) and raised core operating margin to around 39% (up from 37%).
